127 related articles for article (PubMed ID: 17536884)
1. Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease.
Lyubimova NV; Kushlinsky NE; Lichinitser MR; Schlosser K
Clin Drug Investig; 2003; 23(11):707-16. PubMed ID: 17536884
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.
Pecherstorfer M; Rivkin S; Body JJ; Diel I; Bergström B
Clin Drug Investig; 2006; 26(6):315-22. PubMed ID: 17163265
[TBL] [Abstract][Full Text] [Related]
3. Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis.
Fidan E; Yildiz B; Kavgaci H; Ozdemir F; Aydin F
Contemp Oncol (Pozn); 2012; 16(2):176-8. PubMed ID: 23788873
[TBL] [Abstract][Full Text] [Related]
4. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Mystakidou K; Stathopoulou E; Parpa E; Kouloulias V; Kouskouni E; Vlahos L
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1303-10. PubMed ID: 18504612
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis treatment: why ibandronic acid?
Rossini M; Orsolini G; Adami S; Kunnathully V; Gatti D
Expert Opin Pharmacother; 2013 Jul; 14(10):1371-81. PubMed ID: 23650954
[TBL] [Abstract][Full Text] [Related]
7. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
[TBL] [Abstract][Full Text] [Related]
8. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Pecherstorfer M; Diel IJ
Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
[TBL] [Abstract][Full Text] [Related]
9. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ
J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
[TBL] [Abstract][Full Text] [Related]
12. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
[TBL] [Abstract][Full Text] [Related]
13. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Luedders DW; Steinhoff J; Thill M; Rody A; Bohlmann MK
Anticancer Res; 2015 Mar; 35(3):1797-802. PubMed ID: 25750345
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
16. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
17. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
19. Intravenous ibandronate: in the treatment of osteoporosis.
Croom KF; Scott LJ
Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.
Kucukzeybek Y; Gorumlu G; Cengiz E; Karabulut B; Sezgin C; Atmaca H; Sanli UA; Uzunoglu S; Uslu R
J Int Med Res; 2010; 38(5):1663-72. PubMed ID: 21309480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
